用于轻中度阿尔茨海默病的近红外光治疗设备(NirsCure-03A)
一项关于近红外光治疗设备对轻度至中度阿尔茨海默病患者疗效和安全性的多中心、随机、双盲、假对照研究 (NirsCure-03A)
This study is a multicenter, randomized, double-blind, sham-device-controlled clinical trial.
A total of 320 patients with mild to moderate Alzheimer's disease (AD) are planned to be enrolled. Central stratified block randomization will be applied, with stratification based on disease severity (mild vs. moderate) and Aβ-PET subgroup center status (yes vs. no). Participants will be randomly assigned to either the treatment group or control group in a 1:1 ratio. After enrollment, participants will complete the treatment at home during a 52-week double-blind period. The treatment group will receive therapy using a near-infrared light therapy device, while the control group will use sham device. Both investigators and participants will remain blinded to treatment allocation throughout the double-blind period. Participants who complete the 52-week double-blind treatment period may choose to enter an open-label extension and receive an additional 26 weeks of active near-infrared light therapy.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Yi Tang, MD, PhD
- 电话号码:+86 13811021432
- 邮箱:tangyi@xwhosp.org
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100191
- 招聘中
- Peking University Third Hospital
-
接触:
- Weizhong Xiao, MD, PhD
- 电话号码:+86 15611908691
-
Beijing、Beijing Municipality、中国、100053
- 招聘中
- Xuanwu Hospital, Capital Medical University
-
接触:
- Yi Tang, MD, PhD
- 电话号码:+86 13811021432
- 邮箱:tangyi@xwhosp.org
-
Beijing、Beijing Municipality、中国、100032
- 招聘中
- Peking University First Hospital
-
接触:
- Yongan Sun, MD, PhD
- 电话号码:+86 13391705678
-
Beijing、Beijing Municipality、中国、100730
- 招聘中
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
-
接触:
- Jing Yuan, MD, PhD
- 电话号码:+86 18601105034
-
Beijing、Beijing Municipality、中国、100050
- 招聘中
- Beijing Friendship Hospital, Capital Medical University
-
接触:
- Yongbo Zhang, MD, PhD
- 电话号码:+86 13552909549
-
-
Hebei
-
Shijiazhuang、Hebei、中国、050000
- 招聘中
- Shijiazhuang People's Hospital
-
接触:
- Jianping Zhang, MD, PhD
- 电话号码:+86 17603116783
-
-
Inner Mongolia
-
Baotou、Inner Mongolia、中国、014040
- 招聘中
- Baotou Central Hospital
-
接触:
- Furu Liang, MD, PhD
- 电话号码:+86 13664077877
-
-
Jiangsu
-
Suzhou、Jiangsu、中国、215006
- 招聘中
- The First Affiliated Hospital of Soochow University
-
接触:
- Qun Xue, MD, PhD
- 电话号码:+86 13013813620
-
Suzhou、Jiangsu、中国、215004
- 招聘中
- The Second Affiliated Hospital of Soochow University
-
接触:
- Chunfeng Liu, MD, PhD
- 电话号码:+86 13606210609
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710061
- 招聘中
- The First Affiliated Hospital of Xi'an Jiaotong University
-
接触:
- Jin Wang, MD, PhD
- 电话号码:+86 13572208524
-
Xi'an、Shaanxi、中国、710068
- 招聘中
- Shaanxi Provincial People's Hospital
-
接触:
- Rui Li, MD, PhD
-
Xi'an、Shaanxi、中国、710038
- 招聘中
- Tangdu Hospital, Air Force Medical University
-
接触:
- Wei Zhang, MD, PhD
- 电话号码:+86 13891955100
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200127
- 招聘中
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
接触:
- Qun Xu, MD, PhD
- 电话号码:+86 13301679717
-
Shanghai、Shanghai Municipality、中国、200040
- 招聘中
- Huashan Hospital, Fudan University
-
接触:
- Qianhua Zhao, MD, PhD
-
Shanghai、Shanghai Municipality、中国、200030
- 招聘中
- Shanghai Mental Health Center
-
接触:
- Xia Li, MD, PhD
- 电话号码:+86 13774272543
-
Shanghai、Shanghai Municipality、中国、201399
- 招聘中
- Pudong Hospital, Fudan University
-
接触:
- Yunxia Li, MD, PhD
- 电话号码:+86 13636370312
-
-
Shanxi
-
Taiyuan、Shanxi、中国、030001
- 招聘中
- The First Hospital of Shanxi Medical University
-
接触:
- Yang Li, MD, PhD
- 电话号码:+86 15035182003
-
Taiyuan、Shanxi、中国、030001
- 招聘中
- Shanxi Bethune Hospital
-
接触:
- Xiaolei Liu, MD, PhD
- 电话号码:+86 13934643261
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300052
- 招聘中
- General Hospital, Tianjin Medical University
-
接触:
- Nan Zhang, MD, PhD
- 电话号码:+86 13752128310
-
Tianjin、Tianjin Municipality、中国、300060
- 招聘中
- Tianjin Huanhu Hospital
-
接触:
- Pan Li, MD, PhD
- 电话号码:+86 13114881943
-
Tianjin、Tianjin Municipality、中国、300121
- 招聘中
- Tianjin People's Hospital
-
接触:
- Meiyun Zhang, MD, PhD
- 电话号码:+86 13102017703
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310009
- 招聘中
- The Second Affiliated Hospital, Zhejiang University School of Medicine
-
接触:
- Baorong Zhang, MD, PhD
- 电话号码:+86 13958167260
-
Hangzhou、Zhejiang、中国、310015
- 招聘中
- Affiliated Hospital of Hangzhou Normal University
-
接触:
- Jinghua Wang, MD, PhD
- 电话号码:+86 15068892292
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Male or female participants aged between 50 to 85 years old (inclusive).
-
Participants must have at least 4 years of formal education and be capable of completing cognitive and other protocol-specified assessments.
-
Documented progressive memory decline for ≥12 months prior to screening.
-
Meets the core clinical diagnostic criteria for mild to moderate AD dementia (stages 4-5), according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) 2018 research framework and the AA workgroup 2024 update.
-
Evidence of positive brain amyloid pathology, demonstrated by at least one of the following:
- Positive Aβ-PET scan (historical positive result acceptable); or
- Positive Cerebrospinal fluid (CSF) Aβ testing (historical positive result acceptable).
-
Mini-Mental State Examination (MMSE) total score between 15 and 26 inclusive (between 12 and 22 for participants with an elementary school education level).
-
Clinical Dementia Rating (CDR) Global of 1 or 2, and the CDR-Memory Box scores ≥ 0.5.
-
If receiving acetylcholinesterase inhibitor or memantine, participants must be on a stable dose for at least 12 weeks prior to baseline.
-
Must have at least one reliable study partner who can accompany the participant to complete daily treatment. The study partner should have a close relationship with the participant and sufficient knowledge to accurately report on cognition, function, behavior, safety, and protocol compliance. The study partner must be able to communicate with study staff via phone or WeChat, attend required on-site visit, provide informed consent to supporting follow-up throughout the study.
-
The participant, study partner, or legally authorized representative voluntarily agrees to participate and provides written informed consent prior to any study procedures.
Exclusion Criteria:
-
Presence of any diagnosis other than AD that could cause dementia or cognitive decline, including but not limited to: vascular dementia; Central nervous system infections (e.g., HIV, neurosyphilis); Creutzfeldt-Jakob disease; Huntington's disease; Parkinson's disease; Lewy body dementia; Traumatic brain injury-related dementia; Dementia caused by physical and chemical factors (e.g., drug toxicity, alcohol intoxication, carbon monoxide poisoning); significant systemic diseases (e.g., hepatic or pulmonary encephalopathy); Intracranial space-occupying lesions (e.g., subdural hematoma, brain tumors); or dementia clearly attributable to endocrine disorders, vitamin deficiencies, or other identifiable causes.
-
Brain MRI demonstrating significant pathological findings, including but not limited to:
- More than two infarcts with a diameter > 2 cm, or a single infarct involving critical regions (thalamus, hippocampus, entorhinal cortex, parahippocampal cortex, angular gyrus, or other cortical and subcortical gray matter nuclei);
- Extensive white matter hyperintensities (Fazekas score ≥ 3);
- Space-occupying lesions such as abscesses or brain tumors. Lesions judged by the investigator to have no clear clinical significance do not require exclusion.
-
History of transient ischemic attack (TIA), stroke, or seizure within 6 months of screening.
-
Hachinski Ischemic Score (HIS) > 4.
-
Hamilton Depression Rating Scale (HAMD-17) total score > 10.
-
Diagnosis of a psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) at screening, including schizophrenia or other psychotic disorders, bipolar disorder, major depressive disorder, or delirium.
-
Known history or laboratory confirmation of HIV infection or neurosyphilis at screening.
-
Severe cardiovascular disease, including New York Heart Association (NYHA) class III or IV heart function; Severe or unstable angina, or newly developed unstable angina within 3 months prior to screening (with objective clinical evidence such as cardiac enzyme abnormalities or dynamic ST-T changes on electrocardiogram); Acute myocardial infarction within 6 months prior to screening.
-
Severe dysfunction of major organs (heart, lungs, liver, kidneys, etc.), or any medical condition that, in the opinion of the investigator, could render the participant unsuitable for this study or interfere with participation.
-
Current or prior treatment with any anti-amyloid monoclonal antibody (e.g., aducanumab, lecanemab, or donanemab).
-
Prior or planned lymphaticovenous anastomosis (LVA) of the cervical deep lymphatic vessels.
-
Participation in any interventional clinical trial involving a drug or medical device within the 30 days prior to screening, except for observational studies or verified placebo-group participation in a previous interventional trial.
-
History of severe head trauma or implanted cranial devices (e.g., bone screws, bone plates, prior cranial surgery, deep brain stimulators); Contraindications to MRI (e.g., claustrophobia, pacemakers/defibrillators, ferromagnetic metal implants); unwilling to undergo MRI examination.
-
Contraindications to PET or allergy to Aβ-PET tracer (except participants enrolled based solely on CSF Aβ positivity). Participants with uncontrolled abnormal blood glucose, allergy to FDG tracer, or any other investigator-judged contraindications are ineligible for the FDG-PET substudy.
-
History of malignancy within 5 years prior to screening, except for:
- Adequately treated basal or squamous cell skin carcinoma, or cervical dysplasia;
- Adequately treated Stage I in situ cervical cancer ≥ 2 years prior to screening without recurrence;
- Prostate cancer confined to the prostate, adequately treated (e.g., surgery, radiotherapy, or active surveillance), with stable prostate-specific antigen (PSA) levels for ≥ 2 years prior to screening;
- Non-metastatic breast cancer, adequately treated and without recurrence.
-
Women who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential not using highly effective contraception.
-
Any other condition that, in the opinion of the investigator, may compromise the participant's safety, interfere with protocol adherence, or confound study results.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
假比较器:Sham device
Device: NirsCure 6000 sham device (once daily for 30 minutes, six times per week) |
Sham device for 52 weeks during the double-blind period (once daily for 30 minutes, six times per week). Participants entering the open-label extension will receive active near-infrared light therapy for an additional 26 weeks. |
|
实验性的:Near infrared light therapy
Device: NirsCure 6000 Near-infrared light therapy (once daily for 30 minutes, six times per week) |
Near-infrared light therapy for 52 weeks during the double-blind period (once daily for 30 minutes, six times per week). Participants entering the open-label extension will receive an additional 26 weeks of active treatment with the same regimen. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Alzheimer's Disease Assessment Scale, cognitive subscale 13 (ADAS-Cog13)
大体时间:52 weeks
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog13) score at 52-Weeks. The ADAS-Cog13 score ranges from 0 to 85, with higher scores indicating greater cognitive impairment. |
52 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Integrated Alzheimer's Disease Rating Scale (iADRS)
大体时间:52 weeks
|
Change from baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) score at 52-Weeks. The iADRS score ranges from 0 to 144, with higher scores indicating better overall cognitive and functional performance. |
52 weeks
|
|
Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL)
大体时间:52 weeks
|
Change from baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) score at 52-Weeks. The ADCS-ADL score ranges from 0 to 78, with higher scores indicating better functional ability in activities of daily living. |
52 weeks
|
|
Clinical Dementia Rating - Sum of Boxes (CDR-SB)
大体时间:52 weeks
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) score at 52-Weeks. The CDR-SB score ranges from 0 to 18, with higher scores indicating greater cognitive and functional impairment. |
52 weeks
|
|
Mini-Mental Status Examination (MMSE)
大体时间:52 weeks
|
Change from baseline in Mini-Mental State Examination (MMSE) score at 52-Weeks. The MMSE score ranges from 0 to 30, with higher scores indicating better cognitive function. |
52 weeks
|
|
ADAS-Cog13
大体时间:13, 26 and 39 weeks
|
Change from baseline in the ADAS-Cog13 at Week 13, 26 and 39 |
13, 26 and 39 weeks
|
|
ADAS-Cog13
大体时间:81 weeks
|
Change from baseline in the ADAS-Cog13 at Week 81 |
81 weeks
|
|
iADRS
大体时间:81 weeks
|
Change from baseline in the iADRS at Week 81 |
81 weeks
|
|
ADCS-ADL
大体时间:81 weeks
|
Change from baseline in the ADCS-ADL at Week 81 |
81 weeks
|
|
CDR-SB
大体时间:81 weeks
|
Change from baseline in the CDR-SB at Week 81 |
81 weeks
|
|
MMSE
大体时间:81 weeks
|
Change from baseline in the MMSE at Week 81 |
81 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- NirsCure-03A
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.